 So during the EHA 2019 in Amsterdam, we heard a lot about new drugs, new strategies in myeloma. Very promising results. I would like to focus on four topics. First, we could call it a treat earlier. And that is related to the subset of patients who have a small during multiple myeloma. So the IMWG conducted a retrospective study and described a new prognostic score. Very easy actually to realize. Everybody can do it. And predicting of a progression of 50% within two years. So this is, we will see, but this is again a very easy new prognostic score for small during myeloma. And also there is a therapeutic abstract on the treatment of these high risk, small during myeloma, with revlimid or no treatment. And they showed that there is a benefit to treat earlier, these small during myeloma with revlimid only, increasing dramatically the PFS. And actually that may be a change in the daily practice in the future. So that's the first point, treat earlier if I could say. Second point, and this is again about monoclonal antibodies and mostly anti-CD38. Philippe Moreau presented for the transplant eligible patients, the Cassiopeia study that was performed mostly by the IFM, showing a high response rate, combining VTD, Velcade Thalidomide Dex plus Daratumumab, before the transplant and in consolidation after the transplant. So this is the first upfront combination in the transplant eligible patients, a trial showing high efficacy adding Daratumumab to the standard VTD regimen. We heard also in the relapse setting this time, the ICAIA trial combining pomalidomide plus DEX plus a new CD30, anti-CD38 monoclonal antibody namely Isatuximab. And in this setting, the results were compared to without the Isatuximab and the results were really encouraging in favor of adding Isatuximab to pomalidomide plus DEX, especially because the patients who were enrolled in this trial were mostly, if not almost all of them, refractory to lenalidomide and as you know today, this is a real issue in the relapse setting. How do we treat patients who relapse on lenalidomide or who are primary refractory? So this is a very important study. So that was the second point, monoclonal antibodies and with anti-CD38 target. The third topic that I would like to draw your attention on is do we still need to do autologous stem cell transplantation? You know this is a very major issue in the field of myeloma treatment and the IFM published not too long ago that indeed we should still do it, but you should have a look at the so-called Forte trial presented by Francesca Gay from Torino, Italy and without going into the details of the trial, she compared KRD, Carthusomy, Breville Middex induction, autologous stem cell transplantation plus KRD consolidation versus KRD only, 12 cycles without autologous stem cell transplantation and she showed that actually the results were quite similar with or without autologous stem cell transplantation but during this meeting, the EHA meeting, she updated the results and she was able to show that actually it remains very important especially for the high-risk myeloma for this subset of patients you really need to do the autologous stem cell transplantation. So this is the third subject, topics. The fourth one is also a very interesting one. It is about steroids. As you know, there are no real guidelines on how long should we keep steroids. There's no question that steroids is an important part of myeloma treatment but we may give too much steroids if I may say to our patients. Actually, Alexandra Larroca from Italy presented a study comparing Revlimiddex until progression for old patient population versus Revlimiddex, nine cycles, nine cycles and then Revlimid only, so without steroids and she was able to show that actually you don't have worse results without the long-term treatment with steroids, even better without it and of course less toxicity. So this is important because probably in the near future we will still use steroids but with a shorter time probably. So again during EHA 2019 we had new information about the so-called new drugs and I would like to start with what we call now the BCMA therapies and that includes, why do we call them BCMA therapies? Because the target on the malignant plasmocytes is BCMA. So we have actually three treatment approaches. We have of course the CAR T-cells and this was published recently in the New England Journal of Medicine by New Upper Raj from Boston and she updated again these very encouraging results. We also have the so-called bytes, base-specific antibodies that has been also updated during this congress and finally also a very interesting approach. It's called the antibody drug conjugate, ADC treatment. It's a monoclonal antibody targeting BCMA and carrying a chemotherapy and the results are very encouraging also. We also had an update on more targeted therapies such as venetoclax and as you know it's particularly efficacious for patients who have the translocation 11-14 and it's also very active in combination with a proteasominibiter. We also heard about selinexor which is also in development and a new image developed by cell gene, apparently very encouraging especially also for patients who have become refractory to lenalidomide and pomalidomide. So all together this was a very very exciting congress for my Loma.